NCT04253561 2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1 Completed
Clinical Trials
177 trialsNCT01853748 2026-02-19
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
Phase 2 Completed
NCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
NCT05730712 2026-02-06
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT01796197 2026-02-05
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03095352 2025-12-22
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
University of California, San Francisco
Phase 2 Completed
NCT02654119 2025-12-12
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
Phase 2 Completed
NCT01373710 2025-11-24
HIT
Institut Curie
Phase 1/2 Completed
NCT01771458 2025-11-24
SHIVA
Institut Curie
Phase 2 Completed
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03264547 2025-09-29
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Japan Breast Cancer Research Group
Phase 3 Completed
NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
NCT07115095 2025-08-11
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Shaanxi Provincial Cancer Hospital
Phase NA Completed
NCT02252887 2025-07-25
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03094052 2025-06-26
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Phase 2 Completed
NCT07009600 2025-06-06
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Completed
NCT01745965 2025-02-27
ADAPT; T-DM1
West German Study Group
Phase 2 Completed
NCT01817452 2025-02-26
ADAPT
West German Study Group
Phase 2 Completed
NCT02488564 2025-02-03
met-HEReMYTA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT00470704 2024-12-19
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02578368 2024-11-12
FLOT5
Krankenhaus Nordwest
Phase 3 Completed
NCT01921335 2024-11-06
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04307329 2024-10-22
MIMOSA
The Netherlands Cancer Institute
Phase 2 Completed
NCT01340430 2024-05-09
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase 2 Completed
NCT00796978 2024-05-01
Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02448420 2024-04-18
PATRICIA II
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT00618657 2024-02-28
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
University of California, Irvine
Phase 2 Completed
NCT03783936 2023-12-19
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT03845270 2023-12-19
R2D2
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT01387295 2023-12-11
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Herlev Hospital
Phase 2 Completed
NCT01106898 2023-09-28
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
University of Nebraska
Phase 2 Completed
NCT02066532 2023-08-24
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Columbia University
Phase 1/2 Completed
NCT05997524 2023-08-18
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase 2 Completed
NCT05931042 2023-07-05
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
Rawalpindi Medical College
Completed
NCT01367002 2023-05-17
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Yale University
Phase 2 Completed
NCT03988036 2023-05-15
Keyriched-1
West German Study Group
Phase 2 Completed
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01922921 2023-04-18
Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
University of Washington
Phase 1/2 Completed
NCT01875367 2023-04-05
ChangHER-SC
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT00258960 2023-04-04
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT00841828 2023-03-31
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT01306942 2023-03-30
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00129896 2023-03-06
Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT03364348 2022-10-19
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
Stanford University
Phase 1 Completed
NCT03705429 2022-08-19
A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Completed
NCT00436566 2022-08-05
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT02789657 2022-05-19
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Brown University
Phase 2 Completed
NCT01670877 2022-04-15
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Washington University School of Medicine
Phase 2 Completed